AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 22 min read$MIRM

Peetz Christopher sold $666K of MIRM

Peetz Christopher (CHIEF EXECUTIVE OFFICER) sold 6,926 shares of Mirum Pharmaceuticals, Inc. (MIRM) at $96.15 ($0.67M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Peetz Christopher
Published Jun 2, 2026, 11:50 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 11:54 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$MIRM
Neutral
medium confidence
Mentioned
$MIRM
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MIRMNeutralLow
01

Why it matters

The disclosure can influence short-term sentiment and order flow, but it does not, by itself, change company fundamentals.

02

Market read

A routine 10b5-1 insider sale is now disclosed; expect limited fundamental read-through.

03

What to watch

Traders may overreact to insider selling; the key differentiator is whether there are concurrent positive catalysts (not mentioned here) or unusual sale size relative to prior filings (not provided).

Relevance 6/10Novelty 6/10Timing: Filed today; sale occurred 2026-06-01 and is now publicly disclosed.

Background

SEC Form 4 reports insider transactions by company officers/directors; 10b5-1 plans are pre-arranged to trade without timing discretion.

Company-level read

Ticker impact

$MIRMNeutralMedium confidence
Context

Mirum Pharmaceuticals CEO Christopher Peetz sold 6,926 shares in an open-market transaction for ~$665.9K under a pre-arranged 10b5-1 plan.

Expected impact

Low-to-moderate short-term sentiment drag possible; limited fundamental impact expected.

Evidence & confidence

The filing is a routine insider transaction and explicitly tied to a pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.

Market effects

Sector

Minimal; this is company-specific insider activity with no stated operational/regulatory catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because it’s a 10b5-1 plan, the sale may reflect scheduled liquidity rather than bearish expectations; price reaction may be muted.

Key entities

  • issuer
    Mirum Pharmaceuticals, Inc.

    Subject of the Form 4 insider sale by its CEO.

  • insider
    Peetz Christopher

    CEO who sold 6,926 shares on 2026-06-01 under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 5
$MIRMMed

Mirum Pharmaceuticals, Inc. (MIRM): Results of Operations and Financial Condition

Mirum Pharmaceuticals, Inc. (MIRM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mirm-20260805xexx991.htm EX-99.1 Document Exhibit 99.1 Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update – Q2 2026 net product sales of $176 million – 2026 net product sales guidance increased to $680 million to $700 millio

SEC EDGAR 8-K6 min
JUN 4
$MIRMMedAI 9/10

Mirum Pharmaceuticals (MIRM) Reports Positive Phase 2b Data for Volixibat in PSC at EASL Congress

The article is largely promotional and does not provide verifiable details of Mirum Pharmaceuticals’ Phase 2b results for volixibat in PSC. It references an “EASL Congress” update but includes no specific efficacy/safety figures. It also promotes subscription offers and claims about prior stock-pick performance and “upside potential,” without citing sources.

insidermonkey.com6 min
MAY 30
$MIRMMedAI 9/10

Mirum Pharmaceuticals, Inc.: Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

Mirum Pharmaceuticals (Nasdaq: MIRM) presented late-breaking Phase 2b data at EASL 2026. In PSC, volixibat reduced cholestatic pruritus by 2.72 points (placebo-adjusted -1.64; p<0.0001) with 56% vs 26% achieving ≥2-point itch reduction. In HDV, brelovitug met a Week-24 endpoint in 45%/35% vs 0% (delayed). In PFIC, LIVMARLI improved event-free survival vs NAPPED (HR 0.29).

finanznachrichten.de6 min
MAY 25
$MIRMMedAI 8/10

Mirum’s US$600 Million Zero-Coupon Convertible Note Issue Might Change The Case For Investing In Mirum Pharmaceuticals (MIRM)

Simply Wall St discusses Mirum Pharmaceuticals (MIRM) and notes the company’s potential US$600 million zero-coupon convertible note issuance, saying it could affect the investment case. The piece frames “rewards” and “warning signs” based on historical data and analyst forecasts, and cautions it is general information, not financial advice.

finance.yahoo.com4 min